Research map: Polish healthcare professionals’ perceptions of GLP-1 receptor agonists in cardiometabolic risk reduction: a cross-sectional online survey in Poland

Back to the article

Papers in this map

  1. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes · Steven P. Marso · 2016 · 7637 citations · Cited by this paper
  2. Subclinical primary aldosteronism: toward a conceptual framework linking primary aldosteronism and low-renin hypertension · 2026 · Related
  3. 2016 European Guidelines on cardiovascular disease prevention in clinical practice · Massimo Francesco Piepoli · 2016 · 6562 citations · Cited by this paper
  4. Physician and hospital determinants of levothyroxine treatment adequacy in low-risk papillary thyroid carcinoma · 2026 · Related
  5. Once-Weekly Semaglutide in Adults with Overweight or Obesity · John P.H. Wilding · 2021 · 5054 citations · Cited by this paper
  6. The effects of SARS-CoV-2 on bone homeostasis · 2026 · Related
  7. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial · Hertzel C. Gerstein · 2019 · 3179 citations · Cited by this paper
  8. Restless legs syndrome or diabetic peripheral neuropathy: diagnostic dilemmas and clinical insights from a case report · 2026 · Related
  9. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1 · Daniel J. Drucker · 2018 · 2131 citations · Cited by this paper
  10. Association between metabolic syndrome and mortality among breast cancer survivors: a prospective cohort study · 2026 · Related
  11. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment · Sean Wharton · 2025 · 160 citations · Cited by this paper
  12. Association of accelerometer-measured physical activity and the risk of incident cardiovascular diseases within the AHA cardiovascular-kidney-metabolic syndrome 0–4 framework: a prospective cohort of the UK Biobank · 2026 · Related
  13. The Glucagon-Like Peptide 1 Analogue Exendin-4 Attenuates the Nicotine-Induced Locomotor Stimulation, Accumbal Dopamine Release, Conditioned Place Preference as well as the Expression of Locomotor Sensitization in Mice · Emil Egecioglu · 2013 · 157 citations · Cited by this paper
  14. Association of gravidity, parity, and abortion history with nodal metastasis in women with papillary thyroid carcinoma: a retrospective cohort study · 2026 · Related
  15. Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats · Nicole S. Hernandez · 2018 · 126 citations · Cited by this paper
  16. Association between primary aldosteronism and type 2 diabetes and identification of potential molecular mechanisms · 2026 · Related
  17. Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits · Yumin Gao · 2020 · 79 citations · Cited by this paper
  18. Diabetic ketoacidosis associated with pancreatic involvement in a patient with von Hippel-Lindau syndrome: a case report · 2026 · Related
  19. Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus · Kira B. Harris · 2014 · 56 citations · Cited by this paper
  20. Effect of semaglutide 2.4 mg on physical functioning and weight‐ and health‐related quality of life in adults with overweight or obesity: Patient‐reported outcomes from the STEP 1–4 trials · Domenica Rubino · 2024 · 53 citations · Cited by this paper
  21. Glucose-Dependent Insulinotropic Polypeptide in Incretin Physiology: Role in Health and Disease · M. Michael Wolfe · 2025 · 38 citations · Cited by this paper
  22. Gastrointestinal Incretins—Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Disease—State of the Art · Szymon Jonik · 2022 · 33 citations · Cited by this paper
  23. Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists · William Timothy Garvey · 2024 · 33 citations · Cited by this paper
  24. Physician perceptions of GLP-1 receptor agonists in the UK · Louis S. Matza · 2016 · 28 citations · Cited by this paper
  25. Health Care Provider Prescribing Habits and Barriers to Use of New Type 2 Diabetes Medications: A Single-System Survey Study · Aseel Yaseen · 2023 · 25 citations · Cited by this paper
  26. Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes · Sean Wharton · 2025 · 25 citations · Cited by this paper
  27. SGLT2 inhibitors and GLP-1 receptor agonists: which is the best anti-frailty drug? · Pasquale Mone · 2024 · 18 citations · Cited by this paper
  28. Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes · Urna Kansakar · 2026 · 18 citations · Cited by this paper
  29. Patients’ experiences with GLP1-RAs – a systematic review · Christoffer Kraul Ibsen · 2025 · 17 citations · Cited by this paper
  30. Clinical features modifying the cardiovascular benefits of GLP-1 receptor agonists: a systematic review and meta-analysis · Arzu Kalaycı · 2025 · 17 citations · Cited by this paper
  31. Lipid profile changes induced by glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis · Yuna Chae · 2024 · 16 citations · Cited by this paper
  32. Efficacy and Safety of Glucagon‐Like Peptide‐1 Agonists for Psychiatric Symptoms: A Systematic Review · Shakila Meshkat · 2025 · 12 citations · Cited by this paper
  33. SGLT2 inhibitors and GLP-1 receptor agonists: impact on mortality in diabetic patients with cardiovascular disease · Ziad Arow · 2025 · 11 citations · Cited by this paper
  34. Knowledge gap and prescribing patterns of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors among Chinese doctors · Jing Liu · 2024 · 10 citations · Cited by this paper
  35. From needles to pills: oral GLP-1 therapy enters the obesity arena · Gaetano Santulli · 2025 · 9 citations · Cited by this paper
  36. Perceptions of injectable therapies with cardiovascular benefit: an ACNAP survey of healthcare professionals to explore facilitators and barriers · Rani Khatib · 2021 · 8 citations · Cited by this paper
  37. Barriers in prescribing antidiabetic medications with cardiovascular benefits: practice, experience, and attitudes of GPs in Croatia · Tomislav Kurevija · 2025 · 8 citations · Cited by this paper
  38. The effects of GLP-1 agonists on HbA1c and insulin dose among patients with type 1 diabetes · Amirah Alhowiti · 2025 · 8 citations · Cited by this paper
  39. The landscape of novel antidiabetic drugs in diabetic HFpEF: relevant mechanisms and clinical implications · Xiaohui Duan · 2025 · 7 citations · Cited by this paper

Source: OpenAlex (CC0)